Mavelertinib

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameMavelertinib
Drug Alias NamePF6747775PF-06747775PFE-X775PF-7775
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR 19del inhibitorsEGFR L858R inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1EGFR T790MEGFR 19del +[4] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A